- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Public goes ape over fibroid patient
When Beta, a 46-year-old gorilla from the Brookfield Zoo in Brookfield, IL, underwent uterine artery embolization for fibroids, some people took exception to her exceptional care.
When Beta, a 46-year-old gorilla from the Brookfield Zoo in Brookfield, IL, underwent uterine artery embolization for fibroids, some people took exception to her exceptional care.
A posting on the Wall Street Journal's health blog scoffed at a gorilla getting top-notch medical care while many humans do not. Initially, Dr. Steven Smith, one of the interventional radiologists on Beta's team, defended the action, as everybody was involved voluntarily. But the comment forced him to ponder why a gorilla could get access to better treatment than some women with uterine fibroids.
He admits that UAE is not the right treatment for everyone, but he questions what appears to be strong resistance from gynecologists to considering the benefits of the minimally invasive procedure. Criticism aside, he admits IRs occasionally get referrals from gynecologists.
"Beta the gorilla was a referral from a gynecologist," he said.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
